CTIS2022-502837-24-00进行中（未招募）1 期
J2A-MC-GZGQ: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) - J2A-MC-GZGQ
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,460
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Be overweight or have excess weight., Have history of at least 1 self-reported unsuccessful dietary effort to lose body weight., Have type 2 diabetes and on stable treatment for Type 2 diabetes for at least 90 days prior to screening., Have been taking up to 3 oral anti-hyperglycemic medications
排除标准
- •Have type 1 diabetes or any other type of diabetes except type 2, Have a change in body weight more than 11 pounds within 90 days before screening., Have medullary thyroid cancer or multiple endocrine neoplasia type 2, Have a history of chronic or acute pancreatitis, Have diabetic retinopathy and/or macular edema requiring acute treatment., Have active or untreated cancer for less than 5 years.
研究者
相似试验
招募中
1 期
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)Type 2 DiabetesCTIS2023-507280-18-00Eli Lilly & Co.520
进行中（未招募）
1 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)Obesity, Overweight, Overweight or ObesityCTIS2022-502839-19-00Eli Lilly & Co.3,000
招募中
1 期
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)Cardiovascular Disease, ObesityCTIS2023-503659-88-00Eli Lilly & Co.1,800
招募中
1 期
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)CTIS2023-508630-34-00Eli Lilly & Co.10,000
进行中（未招募）
1 期
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerProstate CancerCTIS2023-506777-36-00Eli Lilly & Co.304